Cite
The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
MLA
Xiewei Huang, et al. “The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-Analysis.” BMC Cancer, vol. 24, no. 1, Jan. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-023-11722-4.
APA
Xiewei Huang, Yushuai Yu, Shiping Luo, Wenfen Fu, Jie Zhang, & Chuangui Song. (2024). The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis. BMC Cancer, 24(1), 1–10. https://doi.org/10.1186/s12885-023-11722-4
Chicago
Xiewei Huang, Yushuai Yu, Shiping Luo, Wenfen Fu, Jie Zhang, and Chuangui Song. 2024. “The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-Analysis.” BMC Cancer 24 (1): 1–10. doi:10.1186/s12885-023-11722-4.